AVM                                                    breast(15)
 _________________________________________________________________
  adriamycin...... 30 mg/sqm IV day 1 and 28.
  vinblastine..... 6 mg/sqm IV day 1 and 18.
  mitomycin....... 10 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 8 weeks.


  reference...
    Luikart SD.  Witman GB.  Portlock CS. Adriamycin 
    (doxorubicin), vinblastine, and mitomycin C combination 
    chemotherapy in refractory breast carcinoma. Cancer.  
    54(7):1252-5, 1984 Oct 1. 
  abstract...
    Twenty-seven evaluable patients with refractory, metastatic 
    breast carcinoma were treated with Adriamycin (doxorubicin) 30 
    mg/m2 and vinblastine 6 mg/m2 intravenously on days 1 and 28 
    every 8 weeks, and mitomycin C 10 mg/m2 intravenously on day 1 
    every 8 weeks (AVM). There were three complete and six partial 
    responses for a total response rate of 33%. In addition, 2 
    patients had minimal responses, and 10 patients achieved 
    disease stabilization. Median time to disease progression for 
    responders was 116 days (range, 49-812+ days). Drug toxicity 
    was tolerable: 12 patients (44%) experienced significant bone 
    marrow suppression. There were no drug-related deaths. 
    Although AVM appears to be an active drug combination in 
    heavily pretreated patients with metastatic breast carcinoma, 
    the contribution of vinblastine and mitomycin C to single 
    agent Adriamycin in previously treated patients is not clear 
    from this study.